Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts rate Tyra Biosciences “Moderate Buy”: Twelve analysts recommend buying the stock, one rates it a strong buy, while one each recommends holding or selling. The average 12-month price target is $46.90, well above the reported $24.94 share price.
• Tyra reported quarterly adjusted EPS of -$0.69, missing the consensus estimate of -$0.65, and analysts expect a full-year loss of approximately $2.74 per share.
• Institutional investors and hedge funds own 84.14% of TYRA, with several investors increasing or initiating positions during the second quarter. The clinical-stage oncology company is developing targeted small-molecule therapies for genetically defined cancers.

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) has received a consensus rating of "Moderate Buy" from the fifteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $46.90.

TYRA has been the topic of a number of research analyst reports. Jefferies Financial Group reiterated a "buy" rating and set a $42.00 price objective on shares of Tyra Biosciences in a research note on Wednesday, August 5th. HC Wainwright reiterated a "buy" rating and set a $45.00 price target on shares of Tyra Biosciences in a research report on Thursday, May 14th. Wolfe Research assumed coverage on Tyra Biosciences in a research note on Tuesday, May 19th. They issued a "peer perform" rating on the stock. Bank of America upped their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the company a "buy" rating in a report on Wednesday, June 10th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tyra Biosciences in a research note on Friday, July 17th.

Tyra Biosciences Price Performance

TYRA stock opened at $24.94 on Monday. The company has a market capitalization of $1.49 billion, a P/E ratio of -10.39 and a beta of 0.77. The company has a 50-day simple moving average of $29.51 and a 200 day simple moving average of $32.18. Tyra Biosciences has a fifty-two week low of $11.70 and a fifty-two week high of $40.65.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its earnings results on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities analysts anticipate that Tyra Biosciences will post -2.74 EPS for the current year.

Institutional Investors Weigh In On Tyra Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of TYRA. California State Teachers Retirement System grew its stake in shares of Tyra Biosciences by 55,815.5% in the 2nd quarter. California State Teachers Retirement System now owns 783,935 shares of the company's stock worth $24,544,000 after purchasing an additional 782,533 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new stake in Tyra Biosciences during the second quarter valued at approximately $334,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Tyra Biosciences by 125.8% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,688 shares of the company's stock valued at $565,000 after purchasing an additional 9,856 shares during the last quarter. Public Employees Retirement System of Ohio bought a new stake in Tyra Biosciences during the second quarter worth approximately $237,000. Finally, Capstone Investment Advisors LLC bought a new stake in Tyra Biosciences during the second quarter worth approximately $321,000. 84.14% of the stock is owned by institutional investors and hedge funds.

About Tyra Biosciences

Tyra Biosciences NASDAQ: TYRA is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company's pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source